ITCI earnings call for the period ending December 31, 2020.
News & Analysis: Intra-Cellular Therapies
These two biotech companies are safe bargains in today's volatile market.
ITCI earnings call for the period ending October 30, 2020.
Innovation might be worth the high risk up front investment.
These companies show that specialization can be an excellent competitive strategy.
The potential label expansion of lumateperone in bipolar depression could be a major breakthrough.
A nice bounce for the market was overdue.
Investors are reacting enthusiastically to the company's latest clinical results.
ITCI earnings call for the period ending June 30, 2020.
ITCI earnings call for the period ending March 31, 2020.